Dezheng Huo, MD, PhD


Research Interests and Activities

 

Dr. Huo’s research interests focus on the genetic, molecular, and environmental factors underlying etiology, prognosis, and treatment of cancers, particularly as they relate to cancer in underserved populations. His research spans across several areas of cancer epidemiology and clinical epidemiology, including:

  1. Genetic epidemiology of breast cancer, particular in women of African ancestry with the use of genome-wide association and whole genome sequencing approach;
  2. Environmental and lifestyle factors for breast cancer etiology in African women and risk prediction model building, and strategy for cancer screening;
  3. Epigenetics and non-coding RNAs, such as microRNAs in relationship to cancer prognosis and survival;
  4. Investigation of the utilization and effectiveness of cancer treatment in real world using big data;
  5. Prenatal exposure to diethylstilbestrol and clear cell adenocarcinoma of vagina and cervix, as well as other health conditions in later life;
  6. Health disparity in breast cancer outcomes in cohort study with data from eHealth.

 

Web Applications

 

The Online Calculator of the Breast Cancer Risk Prediction Model for African women

http://bcrisktool.uchicago.edu/

A Lookup Tool of the MicroRNA-mRNA Correlations in Breast Tumor

http://microrna.uchicago.edu/

Online Database for the African Breast Cancer Study (private)

http://abcs.uchicago.edu/

  •  

Education

  • Ph.D. (Epidemiology) 2005, University of Illinois at Chicago
  • M.S. (Biostatistics) 2001, University of Illinois at Chicago
  • M.S. (Epidemiology) 1997, Beijing Medical University (Now Peking University Health Science Center)
  • M.D. (Preventive Medicine) 1994, Beijing Medical University

Selected Publications

Gao G, Pierce BL, Olopade OI, Im HK, Huo D. Trans-ethnic predicted expression genome-wide association analysis identifies a gene for estrogen receptor-negative breast cancer. PLoS Genetics 2017; 13(9):e1006727

Huo D, Anderson D, Palmer JR, Herbst AL. Incidence rates and risks of diethylstilbestrol-related clear-cell adenocarcinoma of the vagina and cervix: update after 40-year follow-up. Gynecologic Oncology 2017; 146(3):566-571

Huo D, Hu H, Rhie SK, Gamazon ER, Cherniack AD, Liu J, et al. Comparison of breast cancer molecular features and survival by African and European ancestry in the Cancer Genome Atlas. JAMA Oncology 2017 May 4 [Epub ahead of print]

Daly B, Olopade OI, Hou N, Yao K, Winchester DJ, Huo D. Evaluating the quality of breast cancer care delivery: under- and mis-use of adjuvant endocrine therapy in breast cancer patients in the United States, 2004-2013. JAMA Oncology 2017; 3(7):928-935

Hasan Y, Waller J, Yao K, Chmura SJ, Huo D. Utilization trend and regimens of hypofractionated whole breast radiation therapy in the United States. Breast Cancer Research & Treatment 2017; 162(2):317-328

Huo D, Feng Y, Haddad S, Zheng Y, Yao S, Han YJ et al. Genome-wide association studies in women of African ancestry identified 3q26.21 as a novel susceptibility locus for estrogen receptor negative breast cancer. Human Molecular Genetics 2016; 25(21):4835-4846

Huo D, Clayton WM, Yoshimatsu TF, Chen J, Olopade OI.  Identification of a circulating microRNA signature to distinguish recurrence in breast cancer patients. OncoTarget 2016; 7(34):55231-48

Liu J, Gustafson P, Huo D. Bayesian adjustment for the misclassification in both dependent and independent variables with application to a breast cancer study. Statistics in Medicine 2016; 35(23):4252-63

Drazer MW, Huo D, Eggener SE. National Prostate Cancer Screening Rates After the 2012 US Preventive Services Task Force recommendation discouraging prostate-specific antigen-based screening. Journal of Clinical Oncology 2015; 33(22):2416-23.

Huo D, Hou N, Jaskowiak N, Winchester DJ, Winchester DP, Yao K. Use of Postmastectomy radiotherapy and survival rates for breast cancer patients with T1-T2 and one to three positive lymph nodes. Annals of Surgical Oncology 2015; 22(13):4295-304

Hou N, Ndom P, Jombwe J, Ogundiran T, Ademola A, Morhason-Bello I, Ojengbede O, Gakwaya A, Huo D. An epidemiologic investigation of physical activity and breast cancer risk in Africa. Cancer Epidemiology, Biomarkers & Prevention 2014; 23(12):2748-56

Hou N, Hong S, Wang W, Olopade OI, Dignam JJ, Huo D. Hormone replacement therapy and breast cancer: heterogeneous risks by race, weight, and breast density. Journal of the National Cancer Institute 2013; 105(18):1365-72

Prasad SM, Drazer MW, Huo D, Hu JC, Eggener SE. 2008 US Preventive Services Task Force recommendations and prostate cancer screening rates. JAMA 2012; 307(16):1692-4.

Huo D, Zheng Y, Ogundiran TO, Adebamowo C, Nathanson KL, Domchek SM, et al. Evaluation of 19 susceptibility loci of breast cancer in women of African ancestry. Carcinogenesis 2012; 33(4):835–840.  

Drazer MW, Huo D, Schonberg MA, Razmaria A, Eggener SE. Population-based patterns and predictors of PSA screening among older men in the United States. Journal of Clinical Oncology 2011; 29(13):1736-43.

Huo D, Melkonian S, Rathouz P, Khramtsov A, Olopade OI. Concordance in histological and biological parameters between first and second primary breast cancers. Cancer 2011; 117(5):907-15

Ogundiran TO, Huo D, Adenipekun A, Campbell O, Oyesegun R, Akang E, Adebamowo C, Olopade OI. Case-control study of body size and breast cancer risk in Nigerian women. American Journal of Epidemiology 2010; 172(6):682-90

Huo D, Hetzel JT, Roy H, Rubin RT. Association of colorectal cancer and prostate cancer and impact of radiation therapy. Cancer Epidemiology, Biomarkers & Prevention 2009;18(7):1979-85

Huo D, Ikpatt F, Khramtsov A, Dangou JM, Nanda R, Dignam J, et al. Population differences in breast cancer: survey in indigenous African women reveal overrepresentation of triple negative breast cancer. Journal of Clinical Oncology 2009; 27(27):4515-21

Huo D, Senie RT, Daly M, Buys SS, Cummings S, Ogutha J, et al. Prediction of BRCA mutations using the BRCAPRO model in clinic-based African American, Hispanic, and other minority families in the United States. Journal of Clinical Oncology 2009; 278(10):1184-1190

Olopade OI, Grushko TA, Nanda R, Huo D. Advances in breast cancer: Pathways to personalized medicine. Clinical Cancer Research 2008;14(24):7988-99

Huo D, Adebamowo CA, Ogundiran TO, Akang EE, Campbell O, Adenipekun A, et al. Parity and breastfeeding are protective against breast cancer in Nigerian women. British Journal of Cancer 2008; 98(5):992-6

Huo D, Olopade OI. Genetic testing in diverse populations: are researchers doing enough to get out the correct message? JAMA 2007;298(24):2910-1

Huo D, Ouellet LJ. Needle exchange and injection-related risk behaviors in Chicago: A longitudinal study. Journal of Acquired Immune Deficiency Syndrome 2007; 45(1):108-14

Mestan K, Marks J, Hecox K, Huo D, Schreiber MD. Neurodevelopmental outcomes of premature infants treated with inhaled nitric oxide. New England Journal of Medicine 2005; 355:23-25

Huo D, Lauderdale DS, Li L. Influence of reproductive factors on hip fracture risk in Chinese women. Osteoporosis International 2003; 14(8):694-700

Complete peer-reviewed publications on PubMed +

 

Major Courses

  • HSTD 40500 – Advanced Epidemiologic Methods
  • HSTD 30701 - Epidemiologic Methods

Selected Publications

Gao G, Pierce BL, Olopade OI, Im HK, Huo D. Trans-ethnic predicted expression genome-wide association analysis identifies a gene for estrogen receptor-negative breast cancer. PLoS Genetics 2017; 13(9):e1006727

Huo D, Anderson D, Palmer JR, Herbst AL. Incidence rates and risks of diethylstilbestrol-related clear-cell adenocarcinoma of the vagina and cervix: update after 40-year follow-up. Gynecologic Oncology 2017; 146(3):566-571

Huo D, Hu H, Rhie SK, Gamazon ER, Cherniack AD, Liu J, et al. Comparison of breast cancer molecular features and survival by African and European ancestry in the Cancer Genome Atlas. JAMA Oncology 2017 May 4 [Epub ahead of print]

Daly B, Olopade OI, Hou N, Yao K, Winchester DJ, Huo D. Evaluating the quality of breast cancer care delivery: under- and mis-use of adjuvant endocrine therapy in breast cancer patients in the United States, 2004-2013. JAMA Oncology 2017; 3(7):928-935

Hasan Y, Waller J, Yao K, Chmura SJ, Huo D. Utilization trend and regimens of hypofractionated whole breast radiation therapy in the United States. Breast Cancer Research & Treatment 2017; 162(2):317-328

Huo D, Feng Y, Haddad S, Zheng Y, Yao S, Han YJ et al. Genome-wide association studies in women of African ancestry identified 3q26.21 as a novel susceptibility locus for estrogen receptor negative breast cancer. Human Molecular Genetics 2016; 25(21):4835-4846

Huo D, Clayton WM, Yoshimatsu TF, Chen J, Olopade OI.  Identification of a circulating microRNA signature to distinguish recurrence in breast cancer patients. OncoTarget 2016; 7(34):55231-48

Liu J, Gustafson P, Huo D. Bayesian adjustment for the misclassification in both dependent and independent variables with application to a breast cancer study. Statistics in Medicine 2016; 35(23):4252-63

Drazer MW, Huo D, Eggener SE. National Prostate Cancer Screening Rates After the 2012 US Preventive Services Task Force recommendation discouraging prostate-specific antigen-based screening. Journal of Clinical Oncology 2015; 33(22):2416-23.

Huo D, Hou N, Jaskowiak N, Winchester DJ, Winchester DP, Yao K. Use of Postmastectomy radiotherapy and survival rates for breast cancer patients with T1-T2 and one to three positive lymph nodes. Annals of Surgical Oncology 2015; 22(13):4295-304

Hou N, Ndom P, Jombwe J, Ogundiran T, Ademola A, Morhason-Bello I, Ojengbede O, Gakwaya A, Huo D. An epidemiologic investigation of physical activity and breast cancer risk in Africa. Cancer Epidemiology, Biomarkers & Prevention 2014; 23(12):2748-56

Hou N, Hong S, Wang W, Olopade OI, Dignam JJ, Huo D. Hormone replacement therapy and breast cancer: heterogeneous risks by race, weight, and breast density. Journal of the National Cancer Institute 2013; 105(18):1365-72

Prasad SM, Drazer MW, Huo D, Hu JC, Eggener SE. 2008 US Preventive Services Task Force recommendations and prostate cancer screening rates. JAMA 2012; 307(16):1692-4.

Huo D, Zheng Y, Ogundiran TO, Adebamowo C, Nathanson KL, Domchek SM, et al. Evaluation of 19 susceptibility loci of breast cancer in women of African ancestry. Carcinogenesis 2012; 33(4):835–840.  

Drazer MW, Huo D, Schonberg MA, Razmaria A, Eggener SE. Population-based patterns and predictors of PSA screening among older men in the United States. Journal of Clinical Oncology 2011; 29(13):1736-43.

Huo D, Melkonian S, Rathouz P, Khramtsov A, Olopade OI. Concordance in histological and biological parameters between first and second primary breast cancers. Cancer 2011; 117(5):907-15

Ogundiran TO, Huo D, Adenipekun A, Campbell O, Oyesegun R, Akang E, Adebamowo C, Olopade OI. Case-control study of body size and breast cancer risk in Nigerian women. American Journal of Epidemiology 2010; 172(6):682-90

Huo D, Hetzel JT, Roy H, Rubin RT. Association of colorectal cancer and prostate cancer and impact of radiation therapy. Cancer Epidemiology, Biomarkers & Prevention 2009;18(7):1979-85

Huo D, Ikpatt F, Khramtsov A, Dangou JM, Nanda R, Dignam J, et al. Population differences in breast cancer: survey in indigenous African women reveal overrepresentation of triple negative breast cancer. Journal of Clinical Oncology 2009; 27(27):4515-21

Huo D, Senie RT, Daly M, Buys SS, Cummings S, Ogutha J, et al. Prediction of BRCA mutations using the BRCAPRO model in clinic-based African American, Hispanic, and other minority families in the United States. Journal of Clinical Oncology 2009; 278(10):1184-1190

Olopade OI, Grushko TA, Nanda R, Huo D. Advances in breast cancer: Pathways to personalized medicine. Clinical Cancer Research 2008;14(24):7988-99

Huo D, Adebamowo CA, Ogundiran TO, Akang EE, Campbell O, Adenipekun A, et al. Parity and breastfeeding are protective against breast cancer in Nigerian women. British Journal of Cancer 2008; 98(5):992-6

Huo D, Olopade OI. Genetic testing in diverse populations: are researchers doing enough to get out the correct message? JAMA 2007;298(24):2910-1

Huo D, Ouellet LJ. Needle exchange and injection-related risk behaviors in Chicago: A longitudinal study. Journal of Acquired Immune Deficiency Syndrome 2007; 45(1):108-14

Mestan K, Marks J, Hecox K, Huo D, Schreiber MD. Neurodevelopmental outcomes of premature infants treated with inhaled nitric oxide. New England Journal of Medicine 2005; 355:23-25

Huo D, Lauderdale DS, Li L. Influence of reproductive factors on hip fracture risk in Chinese women. Osteoporosis International 2003; 14(8):694-700

Complete peer-reviewed publications on PubMed +

 

Major Courses

  • HSTD 40500 – Advanced Epidemiologic Methods
  • HSTD 30701 - Epidemiologic Methods

 

Last updated: Oct 5, 2017

Selected Publications

Gao G, Pierce BL, Olopade OI, Im HK, Huo D. Trans-ethnic predicted expression genome-wide association analysis identifies a gene for estrogen receptor-negative breast cancer. PLoS Genetics 2017; 13(9):e1006727

Huo D, Anderson D, Palmer JR, Herbst AL. Incidence rates and risks of diethylstilbestrol-related clear-cell adenocarcinoma of the vagina and cervix: update after 40-year follow-up. Gynecologic Oncology 2017; 146(3):566-571

Huo D, Hu H, Rhie SK, Gamazon ER, Cherniack AD, Liu J, et al. Comparison of breast cancer molecular features and survival by African and European ancestry in the Cancer Genome Atlas. JAMA Oncology 2017 May 4 [Epub ahead of print]

Daly B, Olopade OI, Hou N, Yao K, Winchester DJ, Huo D. Evaluating the quality of breast cancer care delivery: under- and mis-use of adjuvant endocrine therapy in breast cancer patients in the United States, 2004-2013. JAMA Oncology 2017; 3(7):928-935

Hasan Y, Waller J, Yao K, Chmura SJ, Huo D. Utilization trend and regimens of hypofractionated whole breast radiation therapy in the United States. Breast Cancer Research & Treatment 2017; 162(2):317-328

Huo D, Feng Y, Haddad S, Zheng Y, Yao S, Han YJ et al. Genome-wide association studies in women of African ancestry identified 3q26.21 as a novel susceptibility locus for estrogen receptor negative breast cancer. Human Molecular Genetics 2016; 25(21):4835-4846

Huo D, Clayton WM, Yoshimatsu TF, Chen J, Olopade OI.  Identification of a circulating microRNA signature to distinguish recurrence in breast cancer patients. OncoTarget 2016; 7(34):55231-48

Liu J, Gustafson P, Huo D. Bayesian adjustment for the misclassification in both dependent and independent variables with application to a breast cancer study. Statistics in Medicine 2016; 35(23):4252-63

Drazer MW, Huo D, Eggener SE. National Prostate Cancer Screening Rates After the 2012 US Preventive Services Task Force recommendation discouraging prostate-specific antigen-based screening. Journal of Clinical Oncology 2015; 33(22):2416-23.

Huo D, Hou N, Jaskowiak N, Winchester DJ, Winchester DP, Yao K. Use of Postmastectomy radiotherapy and survival rates for breast cancer patients with T1-T2 and one to three positive lymph nodes. Annals of Surgical Oncology 2015; 22(13):4295-304

Hou N, Ndom P, Jombwe J, Ogundiran T, Ademola A, Morhason-Bello I, Ojengbede O, Gakwaya A, Huo D. An epidemiologic investigation of physical activity and breast cancer risk in Africa. Cancer Epidemiology, Biomarkers & Prevention 2014; 23(12):2748-56

Hou N, Hong S, Wang W, Olopade OI, Dignam JJ, Huo D. Hormone replacement therapy and breast cancer: heterogeneous risks by race, weight, and breast density. Journal of the National Cancer Institute 2013; 105(18):1365-72

Prasad SM, Drazer MW, Huo D, Hu JC, Eggener SE. 2008 US Preventive Services Task Force recommendations and prostate cancer screening rates. JAMA 2012; 307(16):1692-4.

Huo D, Zheng Y, Ogundiran TO, Adebamowo C, Nathanson KL, Domchek SM, et al. Evaluation of 19 susceptibility loci of breast cancer in women of African ancestry. Carcinogenesis 2012; 33(4):835–840.  

Drazer MW, Huo D, Schonberg MA, Razmaria A, Eggener SE. Population-based patterns and predictors of PSA screening among older men in the United States. Journal of Clinical Oncology 2011; 29(13):1736-43.

Huo D, Melkonian S, Rathouz P, Khramtsov A, Olopade OI. Concordance in histological and biological parameters between first and second primary breast cancers. Cancer 2011; 117(5):907-15

Ogundiran TO, Huo D, Adenipekun A, Campbell O, Oyesegun R, Akang E, Adebamowo C, Olopade OI. Case-control study of body size and breast cancer risk in Nigerian women. American Journal of Epidemiology 2010; 172(6):682-90

Huo D, Hetzel JT, Roy H, Rubin RT. Association of colorectal cancer and prostate cancer and impact of radiation therapy. Cancer Epidemiology, Biomarkers & Prevention 2009;18(7):1979-85

Huo D, Ikpatt F, Khramtsov A, Dangou JM, Nanda R, Dignam J, et al. Population differences in breast cancer: survey in indigenous African women reveal overrepresentation of triple negative breast cancer. Journal of Clinical Oncology 2009; 27(27):4515-21

Huo D, Senie RT, Daly M, Buys SS, Cummings S, Ogutha J, et al. Prediction of BRCA mutations using the BRCAPRO model in clinic-based African American, Hispanic, and other minority families in the United States. Journal of Clinical Oncology 2009; 278(10):1184-1190

Olopade OI, Grushko TA, Nanda R, Huo D. Advances in breast cancer: Pathways to personalized medicine. Clinical Cancer Research 2008;14(24):7988-99

Huo D, Adebamowo CA, Ogundiran TO, Akang EE, Campbell O, Adenipekun A, et al. Parity and breastfeeding are protective against breast cancer in Nigerian women. British Journal of Cancer 2008; 98(5):992-6

Huo D, Olopade OI. Genetic testing in diverse populations: are researchers doing enough to get out the correct message? JAMA 2007;298(24):2910-1

Huo D, Ouellet LJ. Needle exchange and injection-related risk behaviors in Chicago: A longitudinal study. Journal of Acquired Immune Deficiency Syndrome 2007; 45(1):108-14

Mestan K, Marks J, Hecox K, Huo D, Schreiber MD. Neurodevelopmental outcomes of premature infants treated with inhaled nitric oxide. New England Journal of Medicine 2005; 355:23-25

Huo D, Lauderdale DS, Li L. Influence of reproductive factors on hip fracture risk in Chinese women. Osteoporosis International 2003; 14(8):694-700

Complete peer-reviewed publications on PubMed +

 

 

 

Major Courses

  • HSTD 40500 – Advanced Epidemiologic Methods
  • HSTD 30701 - Epidemiologic Methods